Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ASPH | Q12797 | 2/20 | 0.64 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.64 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | VNN1 | O95497 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
| ▸ | KLK1 | P06870 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20840602 | 0.90 | KDM4E (0.54) | KDM4EASPHKDM8RIOX2NPC1 | |
| SCHEMBL19422706 | 0.81 | KDM4E (0.58) | KDM4EASPHKDM8RIOX2VNN1 | |
| SCHEMBL1715769 | 0.79 | NPC1 (0.66) | KDM4EASPHKDM8RIOX2NPC1 | |
| SCHEMBL13351975 | 0.78 | NPC1 (0.52) | NPC1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1505239 | 0.78 | ALDH1A1 (0.68) | KDM4EASPHKDM8RIOX2NPC1 | |
| Nitrous Acid SCHEMBL27647918 | 0.78 | NPC1 (0.60) | KDM4EASPHKDM8RIOX2NPC1 | |
| SCHEMBL1467628 | 0.77 | VNN1 (0.54) | KDM4EASPHKDM8HDAC1HDAC6 | |
| SCHEMBL20840603 | 0.76 | NPC1 (0.51) | KDM4EASPHKDM8RIOX2NPC1 | |
| SCHEMBL30996045 | 0.76 | MAPT (0.62) | KDM4ENPC1LMNAHPGDHDAC1 | |
| SCHEMBL784516 | 0.76 | RAB9A (0.62) | KDM4EASPHKDM8NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361760-B2 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361760-B2 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361760-B2 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1656376-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | Avanir Pharmaceuticals (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050124604-A1 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005021546-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | MIF, MSR1, SLC11A2 | KDM4E 3601/4885ASPH 2158/4885KDM8 1579/4885 |
| US-20050124604-A1 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | MIF, MSR1, SLC11A2 | KDM4E 3601/4885ASPH 2158/4885KDM8 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.